Literature DB >> 17261625

Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.

Kim Credito1, Genrong Lin, Peter C Appelbaum.   

Abstract

Time-kill synergy studies testing in vitro activity of DX-619 alone and with added vancomycin, teicoplanin, or linezolid against 101 Staphylococcus aureus strains showed synergy between DX-619 and teicoplanin at 12 to 24 h in 72 strains and between DX-619 and vancomycin in 28 strains. No synergy was found with linezolid, and no antagonism was observed with any combination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261625      PMCID: PMC1855475          DOI: 10.1128/AAC.01517-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  In vitro activity of linezolid against staphylococci.

Authors:  C Cuny; W Witte
Journal:  Clin Microbiol Infect       Date:  2000-06       Impact factor: 8.067

3.  The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

Authors:  K Hiramatsu
Journal:  Am J Med       Date:  1998-05-29       Impact factor: 4.965

4.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

Review 5.  Optimal treatment of complicated skin and skin structure infections.

Authors:  R L Nichols
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

6.  Vancomycin-resistant Staphylococcus aureus--New York, 2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-04-23       Impact factor: 17.586

7.  Methicillin-resistant Staphylococcus aureus in Europe.

Authors:  A Voss; D Milatovic; C Wallrauch-Schwarz; V T Rosdahl; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

8.  Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Authors:  Bulent Bozdogan; Duygu Esel; Cynthia Whitener; Frederick A Browne; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

9.  Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs.

Authors:  Toshinobu Horii; Yasuhiro Suzuki; Akio Monji; Motoki Morita; Hideaki Muramatsu; Yoko Kondo; Matsuko Doi; Akihiro Takeshita; Takashi Kanno; Masato Maekawa
Journal:  Diagn Microbiol Infect Dis       Date:  2003-06       Impact factor: 2.803

10.  Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.

Authors:  Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.